Bone scintigraphy in nasopharyngeal carcinoma

Clin Radiol. 1990 Sep;42(3):166-9. doi: 10.1016/s0009-9260(05)81926-9.

Abstract

One hundred and forty-three patients (Group 1) with histologically proven nasopharyngeal-carcinoma (NPC) had bone scintigraphy with 99Tcm methylenediphosphonate (MDP) or dihydroxypropanediphosphonate (DPD) within 2 months of the initial diagnosis. A further 162 patients (Group 2) had bone scans during the course of follow-up if there were symptoms of bone pain or evidence of metastases at other sites. Twenty-three per cent (33/143) of the newly diagnosed NPC patients (Group 1) had evidence of bone metastases. Of these 143 patients, 101 were T0-T2, 16 were T3 and 25 were T4. Thirty-six patients had no neck nodes (NO), 44 were N1, 25 N2 and 38 N3. Of the 162 patients in Group 2, 96 (59%) had a positive bone scan. The commonest sites for bony metastases from NPC were the spine, ribs, pelvis and lower limbs in order of frequency. There is a highly significant association with the nodal stage but no association with the UICC T staging which is not adequate in nasopharyngeal carcinoma. In our part of the world, bone metastases from NPC are a common cause of an abnormal bone scan.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / secondary*
  • Child
  • Diphosphonates
  • Female
  • Humans
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Nasopharyngeal Neoplasms / pathology*
  • Neoplasm Metastasis
  • Organotechnetium Compounds
  • Radionuclide Imaging
  • Technetium Tc 99m Medronate

Substances

  • Diphosphonates
  • Organotechnetium Compounds
  • technetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acid
  • Technetium Tc 99m Medronate